Needham raised the firm’s price target on Doximity (DOCS) to $75 from $67 and keeps a Buy rating on the shares. The company reported strong Q1 results highlighted by early success in the upsell season, driven by new products, the analyst tells investors in a research note. The firm is especially bullish on Doximity’s two new AI innovations, Scribe and Pathway, which extend its functionality with offerings that are in high demand among physicians in 2025, Needham added.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity price target raised to $62 from $60 at Morgan Stanley
- Doximity price target raised to $75 from $65 at Raymond James
- Doximity price target raised to $65 from $62 at Wells Fargo
- Doximity price target raised to $59 from $50 at Canaccord
- Doximity’s Strong Q1 and AI Innovations Drive Buy Rating Despite Growth Concerns